GENinCode PLC
GENI
Company Profile
Business description
GENinCode PLC principal activity is the development and commercialisation of clinical genetic tests, to provide predictive analysis of risk to a patient's health based on their genes. The company has one operating segment. The company has presence in Spain, UK, United States, Italy, Germany, and Rest of World. The company generates majority of revenue from Spain. Its commercial products are CE-Marked, with CARDIO inCode, THROMBO inCode, and LIPID inCode.
Contact
Oxford Science Park
John Eccles House, Robert Robertson Avenue
OxfordOX4 4GP
GBRT: +44 1865676125
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
46
Stocks News & Analysis
stocks
The World Cup stock you’ve never heard of
This ASX stock is kicking goals at the FIFA World Cup.
stocks
Chart of the Week: Can WiseTech shares finally bounce back?
Market concerns over governance and AI fears have left shares trading well below the fair value.
stocks
Steep downgrade for wide moat share
Regulatory pressures squeeze growth outlook for wide moat ASX share.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,979.30 | 38.70 | 0.43% |
| CAC 40 | 8,252.66 | 183.58 | -2.18% |
| DAX 40 | 24,897.45 | 567.80 | -2.23% |
| Dow JONES (US) | 52,348.39 | 576.76 | -1.09% |
| FTSE 100 | 10,489.04 | 176.84 | -1.66% |
| HKSE | 24,199.46 | 702.57 | 2.99% |
| NASDAQ | 25,870.65 | 51.96 | 0.20% |
| Nikkei 225 | 66,819.05 | 1,437.91 | -2.11% |
| NZX 50 Index | 13,665.18 | 97.61 | -0.71% |
| S&P 500 | 7,482.71 | 21.14 | -0.28% |
| S&P/ASX 200 | 8,785.10 | 47.50 | 0.54% |
| SSE Composite Index | 3,970.88 | 19.36 | -0.49% |